Advertisement
Screener

BIO-TECHNE Corp (TECH) Graph

TECH Revenue Flow

Filed revenue amounts for 2025-07-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $321.19M*; Revenue including tax (m); Cost of revenue $109.80M*; Selling, general and administrative $113.17M*.
  • 2026-03-31: Revenue $311.42M; Revenue including tax (m); Cost of revenue $103.13M; Selling, general and administrative $109.34M.
  • 2025-12-31: Revenue $295.88M; Revenue including tax (m); Cost of revenue $104.60M; Selling, general and administrative $113.69M.
  • 2025-09-30: Revenue $286.56M; Revenue including tax (m); Cost of revenue $98.44M; Selling, general and administrative $116.21M.

Consolidation item

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

TECH revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.IntersegmentElimination-$1.38MOperating Segments$1.21BRevenue$1.22BCost of revenue$415.97MGross profit$799.07MOperating expenses$547.18MOperating income$251.89MOther income, net-$5.80MSelling, general& administrative$452.42MPre-tax income$240.68MIncome tax$58.82MNet income$181.86M

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

TECH revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Royalty$24.99MService$94.30MConsumables$985.12MInstruments$110.63MProduct And Services$1.19BRevenue$1.22BCost of revenue$415.97MGross profit$799.07MOperating expenses$547.18MOperating income$251.89MOther income, net-$5.80MSelling, general& administrative$452.42MPre-tax income$240.68MIncome tax$58.82MNet income$181.86M

Geography

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

TECH revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.APAC ExcludingGreater China$85.82MEMEA Excluding UK$294.22MRest Of World$39.28MCN$104.06MGB$56.28MUS$635.37MRevenue$1.22BCost of revenue$415.97MGross profit$799.07MOperating expenses$547.18MOperating income$251.89MOther income, net-$5.80MSelling, general& administrative$452.42MPre-tax income$240.68MIncome tax$58.82MNet income$181.86M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxCost of revenueSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$321.19M*(m)$109.80M*$113.17M*$137.12M*$16.06M*(m)
2026-03-31$311.42M(m)$103.13M$109.34M$132.79M$20.18M$51.05M
2025-12-31$295.88M(m)$104.60M$113.69M$136.82M$12.78M$38.01M
2025-09-30$286.56M(m)$98.44M$116.21M$140.45M$9.81M$38.19M
2025-03-31$316.18M(m)$101.63M$151.27M$175.85M$15.69M$22.59M
2024-12-31$297.03M(m)$103.14M$121.45M$146.47M$7.99M$34.89M
2024-09-30$289.46M(m)$106.44M$119.16M$143.03M$6.57M$33.60M
2024-03-31$303.43M(m)$98.83M$111.84M$137.60M$12.03M$49.06M
2023-12-31$272.60M(m)$96.01M$115.67M$138.58M$5.92M$27.46M
2023-09-30$276.94M(m)$91.74M$105.33M$129.33M-$1.44M$50.99M
2023-03-31$294.15M(m)$91.98M$99.24M$121.95M$9.98M$70.22M
2022-12-31$271.58M(m)$88.22M$93.01M$115.47M$16.42M$50.01M
2022-09-30$269.65M(m)$90.06M$99.38M$123.28M$13.98M$89.56M
2022-03-31$290.38M(m)$88.92M$89.27M$111.01M$8.63M$60.74M
2021-12-31$269.28M(m)$85.58M$100.69M$121.34M$14.12M$80.17M
2021-09-30$257.72M(m)$86.72M$86.17M$107.78M-$1.60M$69.61M
2021-03-31$243.55M(m)$75.28M$82.60M$99.65M-$48.00K$45.78M
2020-12-31$224.25M(m)$73.35M$83.12M$99.91M$10.22M$46.27M
2020-09-30$204.20M(m)$66.47M$72.60M$88.64M$5.94M$33.40M
2020-06-30(m)$175.83M$62.52M(m)(m)(m)$58.85M
2020-03-31$194.68M$194.68M$64.62M$66.32M$82.27M$10.39M$36.43M
2019-12-31$184.93M$184.93M$63.53M$68.03M$84.41M$30.70M$119.62M
2019-09-30$183.24M$183.24M$64.83M$69.01M$85.09M$3.41M$14.40M
2019-06-30(m)$191.66M$63.41M(m)(m)(m)$16.46M
2019-03-31$184.86M$184.86M$60.25M$64.97M$80.52M$5.22M$44.65M
2018-12-31$174.51M$174.51M$61.49M$63.60M$79.42M$4.21M$17.56M
2018-09-30$162.97M$162.97M$55.37M$67.05M$81.84M$183.00K$17.40M
2018-06-30(m)$180.25M$58.07M(m)(m)(m)$41.70M
2018-03-31$163.97M$163.97M$53.71M$53.28M$67.18M$5.24M$19.74M
2017-12-31$154.15M$154.15M$52.32M$63.77M$77.69M-$27.12M$48.85M
2017-09-30$144.61M$144.61M$46.74M$58.29M$71.84M$7.10M$15.86M
2017-06-30$156.58M$156.58M$54.21M(m)(m)(m)$27.61M
2017-03-31$144.04M$144.04M$47.35M$49.41M$63.18M$8.97M$22.17M
2016-12-31$131.81M$131.81M$43.66M$56.98M$70.26M$7.72M$7.47M
2016-09-30$130.58M$130.58M$43.24M$45.42M$58.19M$8.94M$18.84M
2016-06-30$134.76M(m)$45.07M(m)(m)(m)$25.63M
2016-03-31$130.97M(m)$40.98M$35.22M$46.46M$12.20M$30.29M
2015-12-31$120.91M(m)$39.32M$34.59M$45.56M$9.52M$25.85M
2015-09-30$112.38M(m)$36.99M$33.04M$44.36M$9.14M$22.71M
2015-03-31$114.16M(m)$34.78M$29.09M$39.95M$14.47M$24.29M
2014-12-31$111.95M(m)$36.20M$31.14M$41.16M$9.35M$33.21M
2014-09-30$108.48M(m)$35.41M$28.70M$37.85M$10.69M$23.91M
2014-03-31$95.56M(m)$27.44M$14.67M$22.34M$14.43M$31.64M
2013-12-31$84.02M(m)$25.42M$14.93M$22.85M$11.16M$25.05M
2013-09-30$85.67M(m)$24.55M$14.02M$21.72M$12.23M$27.43M
2013-03-31$80.99M(m)$19.84M$9.98M$17.20M$11.35M$33.12M
2012-12-31$75.08M(m)$19.82M$10.96M$18.36M$12.08M$25.36M
2012-09-30$75.03M(m)$19.44M$10.33M$17.78M$12.32M$25.67M
2012-03-31$83.62M(m)$20.24M$9.90M$17.02M$11.45M$31.76M
2011-12-31$74.66M(m)$19.49M$10.65M$17.49M$12.06M$25.81M
2011-09-30$77.60M(m)$19.21M$10.77M$17.44M$12.98M$27.52M
2011-03-31$76.27M(m)$15.94M$9.29M$15.59M$14.32M$31.06M
2010-12-31$67.71M(m)$15.33M$8.43M$15.03M$11.14M$26.53M
2010-09-30$67.94M(m)$15.35M$7.61M$14.23M$12.58M$26.37M
2010-03-31$70.28M(m)$14.40M$7.67M$14.23M$9.05M$32.39M
2009-12-31$65.52M(m)$13.33M$9.01M$15.64M$11.98M$24.72M
2009-09-30$66.53M(m)$12.90M$8.04M$14.43M$12.94M$26.77M

Revenue and expense 6 month

Period endRevenueCost of revenueSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$582.43M$203.04M$229.90M$277.27M$22.58M$76.19M
2024-12-31$586.49M$209.59M$240.61M$289.50M$14.56M$68.49M
2023-12-31$549.53M$187.75M$221.00M$267.91M$4.49M$78.46M
2022-12-31$541.24M$178.28M$192.39M$238.75M$30.41M$139.56M
2021-12-31$527.00M$172.31M$186.87M$229.12M$12.52M$149.79M
2020-12-31$428.45M$139.82M$155.71M$188.54M$16.17M$79.67M
2020-09-30(m)(m)(m)(m)(m)$33.40M
2019-12-31$368.18M$128.36M$137.04M$169.50M$34.11M$134.02M
2019-09-30(m)(m)(m)(m)(m)$14.40M
2018-12-31$337.48M$116.86M$130.66M$161.26M$4.39M$34.96M
2017-12-31$298.77M$99.06M$122.06M$149.52M-$20.01M$64.71M
2016-12-31$262.39M$86.90M$102.41M$128.45M$16.66M$26.31M
2015-12-31$233.29M$76.31M$67.63M$89.92M$18.66M$48.56M
2014-12-31$220.43M$71.62M$59.84M$79.01M$20.05M$57.12M
2013-12-31$169.69M$49.98M$28.95M$44.57M$23.39M$52.48M
2012-12-31$150.11M$39.26M$21.28M$36.14M$24.40M$51.03M
2011-12-31$152.26M$38.70M$21.42M$34.93M$25.04M$53.33M
2010-12-31$135.65M$30.68M$16.04M$29.26M$23.72M$52.91M
2009-12-31$132.06M$26.23M$17.05M$30.07M$24.91M$51.49M

Revenue and expense 9 month

Period endRevenueRevenue including taxCost of revenueSelling, general and administrativeOperating expensesIncome taxNet income
2026-03-31$893.85M(m)$306.17M$339.24M$410.06M$42.76M$127.24M
2025-03-31$902.67M(m)$311.21M$391.88M$465.35M$30.24M$91.08M
2024-03-31$852.96M(m)$286.58M$332.84M$405.51M$16.51M$127.52M
2023-03-31$835.38M(m)$270.26M$291.62M$360.70M$40.38M$209.78M
2022-03-31$817.37M(m)$261.23M$276.14M$340.13M$21.15M$210.53M
2021-03-31$672.00M(m)$215.10M$238.31M$288.19M$16.12M$125.45M
2020-03-31$562.86M(m)$192.98M$203.36M$251.77M$44.50M$170.45M
2019-03-31$522.34M(m)$177.11M$195.62M$241.78M$9.62M$79.61M
2018-03-31$462.74M$462.74M$152.78M$175.35M$216.70M-$14.77M$84.45M
2017-09-30(m)(m)(m)(m)(m)(m)$15.86M
2017-03-31$406.43M$406.43M$134.26M$151.81M$191.63M$25.64M$48.48M
2016-09-30(m)(m)(m)(m)(m)(m)$18.84M
2016-03-31$364.26M(m)$117.29M$102.84M$136.39M$30.86M$78.85M
2015-03-31$334.58M(m)$106.39M$88.93M$118.97M$34.51M$81.41M
2014-03-31$265.24M(m)$77.42M$43.61M$66.91M$37.82M$84.12M
2013-03-31$231.10M(m)$59.11M$31.27M$53.34M$35.75M$84.15M
2012-03-31$235.88M(m)$58.94M$31.32M$51.95M$36.49M$85.09M
2011-03-31$211.92M(m)$46.62M$25.34M$44.85M$38.04M$83.97M
2010-03-31$202.33M(m)$40.63M$24.71M$44.30M$33.96M$83.88M

Revenue and expense 12 month

Period endRevenueRevenue including taxCost of revenueSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$1.22B(m)$415.97M$452.42M$547.18M$58.82M(m)
2025-06-30$1.22B(m)$429.36M$588.52M$688.02M$25.06M$73.40M
2024-06-30$1.16B(m)$389.33M$466.38M$563.04M$17.58M$168.10M
2023-06-30$1.14B(m)$366.89M$378.38M$470.87M$53.22M$285.26M
2022-06-30$1.11B(m)$349.10M$372.77M$459.91M$38.29M$272.05M
2021-06-30$931.03M(m)$298.18M$324.95M$395.55M$8.59M$140.41M
2020-06-30$738.69M$738.69M$255.50M$260.58M$325.77M$47.18M$229.30M
2019-06-30$714.01M$714.01M$240.51M$264.36M$326.77M$15.94M$96.07M
2018-06-30$642.99M$642.99M$210.85M$240.64M$295.96M-$198.00K$126.15M
2017-06-30$563.00M$563.00M$188.46M$200.44M$253.96M$35.88M$76.09M
2016-06-30$499.02M$499.02M$162.36M$140.88M$186.07M$43.01M$104.48M
2015-06-30$452.25M(m)$144.97M$119.40M$160.25M$46.43M$107.73M
2014-06-30$357.76M(m)$106.35M$60.72M$91.66M$50.44M$110.95M
2013-06-30$310.57M(m)$79.47M$43.38M$72.64M$48.10M$112.56M
2012-06-30$314.56M(m)$78.76M$41.68M$69.59M$49.86M$112.33M
2011-06-30$289.96M(m)$65.03M$35.90M$61.88M$52.68M$112.30M
2010-06-30$269.05M(m)$54.90M$32.70M$57.82M$46.67M$109.78M
2009-06-30$263.96M(m)$55.92M$33.69M$57.25M$50.12M$105.24M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Twist Bioscience Corp (TWST)United States$11.540B-47.21
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
EXELIXIS, INC. (EXEL)United States$14.358B16.15
Immunovant, Inc. (IMVT)United States$7.028B-14.78